FEB 27, 2019 12:00 PM PST

Evaluating Biomarkers for Response to Neoadjuvant Immune Checkpoint Blockade in Melanoma

SPONSORED BY: Nanostring Technologies
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Director, Advanced Applications, NanoString
    Biography
      Sarah Warren is the director of advanced applications at NanoString and leads the early immuno-oncology research program. Prior to joining NanoString, she founded and ran Oncofactor Corp, a biotech focused on discovery of novel immune checkpoint inhibitors and development of therapeutics to block their activity. She has a PhD in immunology from the University of Washington and undergraduate degrees in biochemistry and English from Iowa State University.

    Abstract:

    Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy, or immunotherapy. Previous preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade may lead to increased survival compared to adjuvant treatment1. This webinar will cover recent data from parallel but independent clinical trials explored the efficacy of anti-PD-1 and/or anti-CLTA4 combination immunotherapy plus surgery in patients with early stage melanoma2,3. 

    In each study, safety of the treatment regimen and evidence of immune activity in response to treatment was evaluated. In addition to standard H&E and immunohistochemistry (IHC) staining before and after treatment each study also employed NanoString’s GeoMx™ Digital Spatial Profiler to perform high-plex proteomic analysis with spatial resolution. GeoMx DSP enabled the discovery of markers of antigen presentation (β2M) and T cells (CD3) present on pretreatment tumor biopsies that correlated with clinical efficacy in each study. Additionally, the responses to therapy in each study were strong enough to merit larger trials and continued investigation of the most effective immunotherapy strategy.

    FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

    Learning Objectives: 

    1. Gain an appreciation for how multiplexed spatial profiling via GeoMx can aid in tumor characterization
    2. Understand how GeoMx profiling was used in the 2 studies presented to identify biomarkers of response to immunotherapy and complement other molecular profiling strategies


    Show Resources
    You May Also Like
    NOV 15, 2018 10:00 AM PST
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    FEB 26, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 26, 2019 09:00 AM PST
    DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
    FEB 27, 2019 08:00 AM PST
    C.E. CREDITS
    FEB 27, 2019 08:00 AM PST
    DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
    FEB 20, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 20, 2019 09:00 AM PST
    DATE:  February 20, 2019TIME:  9:00am PST  ...
    NOV 13, 2018 09:00 AM PST
    C.E. CREDITS
    NOV 13, 2018 09:00 AM PST
    DATE:  November 13, 2018TIME:   9:00am PST, 12:00pm ESTExtracellular vesicles (EVs) are cell-secreted nanoparticles that play a pivotal role in intercellular communic...
    NOV 07, 2018 08:00 PM PST
    C.E. CREDITS
    NOV 07, 2018 08:00 PM PST
    DATE: November 7, 2018TIME: 8:00PM PSTExosomes have been shown to have significant roles in cancer including disease progression acting in the tumor micro-environment, metasta...
    Loading Comments...
    Show Resources